Angiosuppressive and Angiostimulatory Effects Exerted by Synthetic Partial Sequences of Endostatin

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5358-5369

  Morbidelli, Lucia ^a   Donnini, Sandra ^a   Chillemi, Francesco ^b   Giachetti, Antonio ^a   Ziche, Marina ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COLLAGEN; COLLAGEN 18; CYSTEINE; ENDOSTATIN; PEPTIDE; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL PROLIFERATION; CORNEA; DISULFIDE BOND; ENDOTHELIUM CELL; ENZYME ACTIVITY; GEL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RABBIT; SYNTHESIS; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; CORNEA; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLASTS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0141809387     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995,
3. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
4. Risau, W. Mechanism of angiogonesis. Nature (Lond.), 386: 671-674, 1997.
5. Hanahan, D., and Folkman, J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
6. Ferrara, N., and Davis Smith, T. The biology of vascular endothelial growth factor. Endocrine Rev., 18: 4-25, 1997.
7. Bickfalvi, A., Klein, S., Pintucci, G., and Rifkin, D. B. Biological roles of fibroblast growth factor-2 (FGF-2). Endocrine Rev., 18: 26-45, 1997.
8. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell, 79: 315-328, 1997.
9. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
10. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblast by p53 regulation of thrombospondin-1. Science (Wash. DC), 265: 1582-1584, 1994.
11. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F., and Sharpe, R. J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science (Wash. DC), 247: 77-79, 1990.
12. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
13. Taddei, L., Chiarugi, P., Brogelli, L., Cirri, P., Magnelli, L., Raugei, G., and Ziche, M. Granger, H. J., Chiarugi, V., and Ramponi, G. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem. Biophys. Res. Commun., 263: 340-345, 1999.
14. Yamaguchi, N., Anard-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., and Olsen, B. R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J., 18: 4424-4423, 1999.
15. Steele, F. R. Can "negative" be positive? Mol. Ther., 5: 338-339, 2002.
16. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y., and Leboulch, P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther., 5: 345-351, 2002.
17. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D., and Eaves, C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther., 5: 352-359, 2002.
18. Taraboletti, G., Morbidelli, L., Donnini, S., Parenti, A., Granger, H. J., Gavazzi, R., and Ziche, M. The heparin binding 25-kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinases and TIMP-2 in endothelial cells. FASEB J., 14: 1674-1676, 2000.
19. Hohenester, E., Sasaki, T., Olsen, B. R., and Timpl, R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution. EMBO J., 17: 1656-1664, 1998.
20. Dryland, A., and Sheppard, R. C. Part 8. A system for solid-phase synthesis under low pressure continuous flow conditions. J. Peptide Synthesis, Chem. Soc. Perkin. Trans. I, 1: 125-138, 1986.
21. Bayer, E. Auf dem Weg zur chemischen Synthese von Proteinen, Angew. Chemie, 103: 117-133, 1991.
22. Schelling, M. E., Meininger, C. J., Hawker, J. R., and Granger, H. J. Venular endothelial cells from bovine heart. Am. J. Physiol., 254: H1211-H1217, 1988.
23. Gualandris, A., Rusnati, M., Belleri, M., Nelli, E. M., Molinari-Tosatti, M. P., Bonardi, F., Parolini, S., Albini, A., Morbidelli, L., Ziche, M., Corallini, A., Possati, L., and Presta, M. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ., 7: 147-160, 1996.
24. Catalioto, R. M., Renzetti, A. R., Criscuoli, M., Morbidelli, L., and Subissi, A. Role of calcium in angiotensin II-induced prostaglandin release and DNA synthesis in rat vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 27: 195-200, 1996.
25. Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H-T., Donnini, S., Granger, H. J., and Bicknell, R. Nitric oxide-synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Investig., 99: 2625-2634, 1997.
26. Brown, K. J., Maynes, S. F., Bezos, A., Maguire, D. J., Ford, M. D., and Parish, C. R. A novel in vitro assay for human angiogenesis. Lab. Investig., 75: 539-555, 1996.
27. Kruger, E. A., Duray, P. H., Tsokos, M. G., Venzon, D. J., Libutti, S. K., Dixon, S. C., Rudek, M. A., Pluda, J., Allegra, C., and Figg, W. D. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem. Biophys. Res. Commun., 268: 183-191, 2000.
28. Dhanabal, M., Ramchandran, R., Volk, R., Stillmann, Ei, E., Lombardo, M., Irauela-Arispe, M., Simons, M., and Sukhatme, V. P. Endostatin: yeast production, mutants and antitumor effect in renal cell carcinoma. Cancer Res., 59: 189-197, 1999.
29. Dixelius, J., Larsson, H., Sazaki, T., Holmqvist, K., Lu, L., Engstrom, A., Timpl, R., Welsh, M., and Claesson-Welsh, L. Endostatin-induced tyrosine kinase signalling trough the Shb adaptor protein regulates endothelial cell apoptosis. Blood, 95: 3403-3411, 2000.
30. Sasaki, T., Larsson, H., Kreuger, J., Salmivirta, M., Claesson-Welsh, L., Lindahl, U., Hohenester, E., and Timpl, R. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J., 18: 6240-6248, 1999.
31. Ferreras, M., Felbor, U., Lenhard, T., Olsen, B. R., and Delaisse, J-M. Generation and degradation of human endostatin proteins by various proteinases. FEBS Letters, 486: 247-251, 2000.
32. Cattaneo, M. G., Pola, S., Francescano, P., Chillemi, F., and Vicentini, L, M. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res., 283: 230-236, 2003.
33. Haas, T. L., and Madri, J. A. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc. Med., 9 (3-4): 70-77, 1999.
34. Davis, G. E., Bayless, K. J., Davis, M. J., and Meininger, G. A. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am. J. Physiol., 156: 1489-1498, 2000.
35. Pfeifer, A., Kessler, T., Silletti, S., Cheresh, D. A., and Verma, I. M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Sci. USA, 97: 12227-12232, 2000.
36. Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., and Martial, J. A. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA, 96: 1246-1251, 1999.
37. Rehn, M., Veikkola, T., Kukk-Valdre, E., Nakamura, H., Ilmonene, M., Lombardo, C., Pihlajaniemi, T., Alitalo, K., and Vuori, K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA, 98: 1024-1029, 2001.
38. 1 integrin, a possible cause of prevention of chondrosarcoma growth. J. Biochem. (Tokyo), 131: 619-626, 2002.